- Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
-
Yoon S, Ryu MH, Yoo C, Beck MY, Ryoo BY, Kang YK
- KMID: 1793034
- J Korean Med Sci.
- 2013 Aug;28(8):1248-1252.
- doi: 10.3346/jkms.2013.28.8.1248
Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib... -
- CITED
-
- Close
- SHARE
-
- Close
